mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Immunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or
microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). However, for proficient
mismatch repair(pMMR)/microsatellite stable(MSS) CRC, the curative effect of PD-1 monoclonal
antibody was poor and most of the data came from stage Ⅳ patients with distant metastasis.
Among the whole CRC patients, more than eighty-five percent were pMMR/MSS CRC. It would be
very inspiring when major CRC patients(pMMR/MSS) could be benefit from immunotherapy. For
T4NxM0 CRC patients, R0 resection was difficult to achieve. If the patients could not got R0
resection, which means the tumors were almost destined to recurrent and patients life time
were counting down. Whether combined treatment of mFOLFOX6+ Bevacizumab+PD-1 monoclonal
antibody could maximize the curative effect was still unknown. This study aims to evaluate
the effect and safety of mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment
combinations in patients with local advanced(T4NxM0) pMMR/MSS CRC.